Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior.
about
Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analysesOral manifestations in the era of HAARTThe combined influence of oral contraceptives and human papillomavirus virus on cutaneous squamous cell carcinomaHigh risk genital papillomavirus infections are not spread vertically.Low avidity of human papillomavirus (HPV) type 16 antibodies is associated with increased risk of low-risk but not high-risk HPV type prevalenceImpact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine - a pilot studySeropositivity against HPV 16 capsids: a better marker of past sexual behaviour than presence of HPV DNA.Prevalence of anti-human papillomavirus type 16, 18, 31, and 58 virus-like particles in women in the general population and in prostitutes.Seroprevalence of human papillomavirus types 6, 11, 16 and 18 in Chinese women.Differences in history of sexual behavior between patients with oropharyngeal squamous cell carcinoma and patients with squamous cell carcinoma at other head and neck sitesNatural immune responses against eight oncogenic human papillomaviruses in the ASCUS-LSIL Triage Study.Oral Sex and HPV: Population Based Indications.Polymer-based enzyme-linked immunosorbent assay using human papillomavirus type 16 (HPV16) virus-like particles detects HPV16 clade-specific serologic responsesPrevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women.Oral sex and the transmission of viral STIsImmunoglobulin A, G, and M responses to L1 and L2 capsids of human papillomavirus types 6, 11, 16, 18, and 33 L1 after newly acquired infection.Sexual behaviour and early coitarche in a national sample of 17 year old Swedish girls.Attack rates of human papillomavirus type 16 and cervical neoplasia in primiparous women and field trial designs for HPV16 vaccination.Cervical mucus antibodies against human papillomavirus type 16, 18, and 33 capsids in relation to presence of viral DNAAge-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global reviewThe epidemiology of conjunctival squamous cell carcinoma in UgandaA prospective study of the relationship between prediagnostic human papillomavirus seropositivity and HPV DNA in subsequent cervical carcinomasSeroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica.Translational mini-review series on vaccines: Monitoring of human papillomavirus vaccination.Human papillomavirus 6 seropositivity is associated with risk of head and neck squamous cell carcinoma, independent of tobacco and alcohol use.Monitoring of human papillomavirus vaccination.Prospective seroepidemiologic study on the role of Human Papillomavirus and other infections in cervical carcinogenesis: evidence from the EPIC cohort.Smoking impairs human papillomavirus (HPV) type 16 and 18 capsids antibody response following natural HPV infection.No excess risk of cervical carcinoma among women seropositive for both HPV16 and HPV6/11.Sero-epidemiological association between human-papillomavirus infection and risk of prostate cancer.Clinical trials of human papillomavirus vaccines and beyond.Nordic biological specimen banks as basis for studies of cancer causes and control--more than 2 million sample donors, 25 million person years and 100,000 prospective cancers.Risk of being seropositive for multiple human papillomavirus types among Finnish and Ugandan women.Population fraction of cervical neoplasia attributable to high-risk human papillomaviruses.Seroprevalence atlas of infections with oncogenic and non-oncogenic human papillomaviruses in Finland in the 1980s and 1990s.Differences in incidence and co-occurrence of vaccine and nonvaccine human papillomavirus types in Finnish population before human papillomavirus mass vaccination suggest competitive advantage for HPV33.A survey of seroprevalence of human papillomavirus types 16, 18 and 33 among children.Seroreactivity to HPV16 virus-like particles as a marker for cervical cancer risk in high-risk populations.Trends in seroprevalence of human papillomavirus type 16 among pregnant women in Stockholm, Sweden, during 1969-1989.Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in colombian women with invasive cervical cancer.
P2860
Q21144710-35B55B92-C0B8-4D92-9BBC-2686E0C9E8E1Q24651801-6F1A3D3F-078C-45F0-8936-32F929E83454Q28387851-DCB2BE9E-E9CB-4FC6-9D56-4A3E41E83EECQ33661321-F457F0CC-077E-4934-818C-77F147889C97Q33924580-F269850E-584D-4753-9F63-A535939EA8B8Q33929216-4FCABAD5-655A-471C-8EF7-021B536215E7Q33936598-C3AD80FF-84D6-493E-B272-D9474096AC63Q33974260-A02C7DFC-B482-4B60-B682-E776AD112C0DQ34310582-0E55C346-5AA1-4500-89EC-ADCCEC7CAFF2Q34367405-F22BF1F7-416B-450D-B3E2-AC3F87090746Q34546550-C8F6222C-C511-4AF4-BC13-FC17B24BB8C4Q34983370-79FF130E-391F-4A73-8BD4-2E76EE3AB46FQ35155632-5CDF250E-F736-4466-B145-442030847559Q35228978-21241B21-AB1F-460F-B988-FC7BAE1F54ACQ35562031-E19418D8-DC9B-42AA-985E-CF935099FC1AQ35562265-7BD402B6-FA6E-4E64-A6FD-BA2765C21C9DQ35562792-BE6E3681-13BC-4A1A-B52B-2D0A843165DBQ35566274-7A7D51EA-1E62-44D8-A755-17E3C7BEF4E6Q36542076-A2EBAB1C-A991-47E8-B487-41B7AE5642BFQ36609068-6465A2D0-E8B8-48D8-BBDC-4916566D333CQ36624010-23D4A83A-105B-491E-8310-1C85C746B1AFQ36645918-39EF0CD6-833C-4D9F-8B93-8FD844A03132Q36671130-302302EC-D24E-4A05-A903-F9D500671DDCQ36793117-AD2712D1-8D54-4C7E-BCE9-6E98D99BC462Q37321783-B320B718-6F3B-436F-8A47-0F5430D01F43Q37808256-D6DD0078-38DE-49AD-AE26-CAD2738C2818Q37845338-9198ADC6-DF82-404E-868B-CEA2ACC02D88Q37855949-EBE2F560-3A5F-4D9E-8C2B-E777C4C9AF57Q37878868-3F4BFD83-CE98-441F-9469-478CE8EB570CQ37881565-C2AF7C10-7A56-49E5-8F21-E0E60EFAFD5FQ38111962-C475DF74-9274-4C66-AFDE-E6115A698F51Q38397934-A2980C16-6F28-4880-870D-0F6360FEE5B3Q38872908-AE65FE14-488B-4CD5-A250-148BCC253D59Q39873630-ECB14FFA-E38A-4F6D-B44C-EEA1721ADC8CQ43620361-AD69D9A1-63C4-455B-B4AF-C86790B8735FQ44038372-6A13B62D-2D47-4C16-97FD-448527B73548Q44687393-3390E001-4426-4B1A-8BB8-37DE108EAF1AQ45044160-F228018F-8D41-43B4-BA18-75E895631AC7Q45103275-519E709D-63FF-4A9A-B96F-318899181EEAQ45733679-E31A9A72-3547-44CF-B5DF-B38AFE74D344
P2860
Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Seropositivities to human papi ...... re markers of sexual behavior.
@en
Seropositivities to human papi ...... re markers of sexual behavior.
@nl
type
label
Seropositivities to human papi ...... re markers of sexual behavior.
@en
Seropositivities to human papi ...... re markers of sexual behavior.
@nl
prefLabel
Seropositivities to human papi ...... re markers of sexual behavior.
@en
Seropositivities to human papi ...... re markers of sexual behavior.
@nl
P2093
P356
P1476
Seropositivities to human papi ...... re markers of sexual behavior.
@en
P2093
Kallings I
Lehtinen M
Schiller JT
Sikström B
P304
P356
10.1093/INFDIS/173.6.1394
P407
P577
1996-06-01T00:00:00Z